Heather Bates is a managing director with BRG in Washington, D.C. and provides consulting and analytical services to life sciences clients and their counsel regarding economic, regulatory, damages, and discovery issues. In particular, her capabilities relate to developing analyses to answer complex questions based on a detailed understanding of disparate but interrelated financial and healthcare data.
Ms. Bates’ consulting work has focused on pharmaceutical, biotech and medical device manufacturers, pharmacies and PBMs facing compliance issues, litigation, disputes, federal and state investigations, regulatory change and other business challenges. She has significant experience in the areas of government pricing (AWP, AMP, Best Price, and ASP), off-label marketing, regulatory compliance, the False Claims Act, anti-kickback laws, state consumer protection statutes, product liability, good manufacturing practices, and contract disputes.
Ms. Bates uses structured and unstructured data to assess allegations of fraud, non-compliance with federal and state regulations and commercial contracts, antitrust activity, and other business conflicts. She develops models that incorporate manufacturer sales, profit and marketing data, medical and pharmaceutical claims data, public healthcare utilization and cost data, Medicare and Medicaid data, and third party vendor data. Her data analysis and models inform life sciences clients and their counsel of potential liability and exposure, allowing them to make data-driven decisions in the face of complex disputes and investigations. She has also been qualified as an expert witness and has provided deposition testimony.
Ms. Bates has 15 years of consulting experience in the life sciences industry. Prior to joining BRG in June 2010, Ms. Bates was with Navigant Consulting and LECG.
University of Virginia
B.A., Economics, 2001
BRG experts assisted outside counsel for a global pharmaceutical company accused of fraudulent promotion of several of its products for indications that were not Food and Drug Administration approved (so-called “off-label” uses).
A pharmaceutical manufacturer retained BRG personnel in relation to a Department of Justice investigation with a central allegation that the manufacturer misstated its best price and underpaid Medicaid rebate.
BRG experts have assisted a number of pharmaceutical manufacturers and their outside counsel with disputes related to allegedly fraudulent and inflated average wholesale prices for drugs in the so-called “AWP matters.”
News & Insights
Seminars & Speaking Engagements
News & Commentary
- AHLAJune 30, 2015